Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

By Tarun Sai LomteApr 18 2024Reviewed by Lily Ramsey, LLM A recent study published in the New England Journal of Medicine conducted a trial of lixisenatide to assess its effects in early Parkinson’s disease.

Lixisenatide is a GLP-1 receptor agonist used to treat type 2 diabetes. Its neuroprotective actions have been demonstrated in animal models of Parkinson’s disease and Alzheimer’s disease. The trial agent was initially administered at 10 μg/day for 14 days and 20 μg/day for the remainder of 12 months. Subjects continued their existing medication for Parkinson’s disease for the first six months at least.

Secondary efficacy endpoints were the change in scores on MDS-UPDRS part III at six months, change in scores on MDS-UPDRS parts I, II, and IV at six and 12 months, and change in total MDS-UPDRS score at 12 months. Efficacy was assessed using Student’s t-test. Participants’ baseline clinical and demographic characteristics were similar between groups. In both groups, the average time from diagnosis was 1.4 years.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialThe first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Source: medical_xpress - 🏆 101. / 51 Read more »

Phase 3 trial shows overall survival benefit from adjuvant therapy in kidney cancer patientsFor the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Source: NewsMedical - 🏆 19. / 71 Read more »